For example, the inhibition of NF-κB by bortezomib (a proteasome inhibitor) sensitized NSCLC to gemcitabine-induced apoptosis, and the silencing of the NF-κB p65/relA subunit with siRNA increased the effectiveness of gemcitabine in a subset of pancreatic cancer cells [18,19]. This evidence concerns the gene NFKB1 and non-small cell lung carcinoma.